Murine monoclonal antibodies for detection of proteins encoded by genes involved in hematologic neoplasia
| Antibody3-150 . | Fixation resistance of epitope . | Immunocytochemical staining pattern on lymphoid and hemopoietic cells . | ||
|---|---|---|---|---|
| Cell site . | Normal cells . | Neoplastic cells . | ||
| BCL-1/Cyclin D117,18 294 | ||||
| 5D4, DCS-6 | Yes3-151 | Nuclear | Negative | Mantle cell lymphoma3-152 |
| BCL-27 | ||||
| Bcl-2/100, Bcl-2/124 | Yes | Cytoplasmic | Broad (but germinal-center B cells negative) | Broad (including follicular lymphoma) |
| BCL-6106 | ||||
| P6-B6a, P6-B6p | Yes3-153 | Nuclear | Mainly germinal-center B cells, some T cells and CD30-positive cells | Mainly follicle-center–derived lymphomas |
| MUM1/IRF4125 | ||||
| MUM1p | Yes | Nuclear | Plasma cells, rare germinal-center B cells; some T cells and CD30-positive cells | MM, HD, most diffuse large B-cell lymphomas, ALCL |
| PAX-5131 | ||||
| Anti-PAX-5 (clone 24) | Yes | Nuclear | B-cell precursors and mature B cells | B-cell neoplasms (including lymphoblastic) |
| TAL-1137 | ||||
| 2TL75, 2TL242, 2TL140, 2TL733-155 | Yes | Nuclear | Erythroid and megakaryocytic cells | T-cell acute lymphoblastic neoplasms (minority) |
| PML154 155 | ||||
| PG-M3,3-1545E10 | Yes | Nuclear (speckled) | Broad (speckled) | Broad (speckled), APL (microgranular) |
| ALK227 228 | ||||
| ALK1, ALKc | Yes | Nuclear and/or cytoplasmic | Negative | ALCL |
| NPM231 232 | ||||
| 37/5.1, NPMc3-159 | Yes | Nuclear | Broad (nuclear) | Broad (nuclear) |
| NA24, NPMa3-160 | Yes | Nuclear | Broad (nuclear) | Broad (nuclear), ALCL with t(2;5) (nuclear and cytoplasmic) |
| Antibody3-150 . | Fixation resistance of epitope . | Immunocytochemical staining pattern on lymphoid and hemopoietic cells . | ||
|---|---|---|---|---|
| Cell site . | Normal cells . | Neoplastic cells . | ||
| BCL-1/Cyclin D117,18 294 | ||||
| 5D4, DCS-6 | Yes3-151 | Nuclear | Negative | Mantle cell lymphoma3-152 |
| BCL-27 | ||||
| Bcl-2/100, Bcl-2/124 | Yes | Cytoplasmic | Broad (but germinal-center B cells negative) | Broad (including follicular lymphoma) |
| BCL-6106 | ||||
| P6-B6a, P6-B6p | Yes3-153 | Nuclear | Mainly germinal-center B cells, some T cells and CD30-positive cells | Mainly follicle-center–derived lymphomas |
| MUM1/IRF4125 | ||||
| MUM1p | Yes | Nuclear | Plasma cells, rare germinal-center B cells; some T cells and CD30-positive cells | MM, HD, most diffuse large B-cell lymphomas, ALCL |
| PAX-5131 | ||||
| Anti-PAX-5 (clone 24) | Yes | Nuclear | B-cell precursors and mature B cells | B-cell neoplasms (including lymphoblastic) |
| TAL-1137 | ||||
| 2TL75, 2TL242, 2TL140, 2TL733-155 | Yes | Nuclear | Erythroid and megakaryocytic cells | T-cell acute lymphoblastic neoplasms (minority) |
| PML154 155 | ||||
| PG-M3,3-1545E10 | Yes | Nuclear (speckled) | Broad (speckled) | Broad (speckled), APL (microgranular) |
| ALK227 228 | ||||
| ALK1, ALKc | Yes | Nuclear and/or cytoplasmic | Negative | ALCL |
| NPM231 232 | ||||
| 37/5.1, NPMc3-159 | Yes | Nuclear | Broad (nuclear) | Broad (nuclear) |
| NA24, NPMa3-160 | Yes | Nuclear | Broad (nuclear) | Broad (nuclear), ALCL with t(2;5) (nuclear and cytoplasmic) |
MM indicates multiple myeloma; HD, Hodgkin disease; ALCL, anaplastic large cell lymphoma; and APL, acute promyelocytic leukemia.
Polyclonal antibodies showing reactivities similar to those of the monoclonal antibodies discussed in this article have been reported for cyclin D1,295 IRF4/ICSAT (Santa Cruz), PAX-5,131 HRX,296 and ALK.220,225 226
Optimal results are obtained after microwave heating and overnight incubation with the primary antibody.
Cyclin D1 expression is observed only rarely in low-grade B-cell malignant diseases other than mantle cell lymphoma.
Only antibody P6-B6p reacts in paraffin sections (dependent on microwave heating in 1 mM EDTA [pH 8.0]).
Antibody 2TL73 has been used to stain paraffin sections, but results are not optimal (excessive background labeling).
Monoclonal antibody PG-M3154 is preferred to antibody 5E10,155,178 whose epitope (between amino acids 448 and 466) is lost in some forms of PML-RARα (eg, bcr3).156 Given the known frequency of involvement of breakpoint region 3 in APL,149 antibody 5E10 is likely to detect no more than 60% of APL cases.
Directed against the carboxy-terminal of NPM (not present in the NPM-ALK fusion protein).
Both directed against the amino-terminal of NPM (present in the NPM-ALK fusion protein).